Cologrx

CologRx is a clinical-stage biotechnology company focused on the prevention and treatment of colorectal cancer through the development of targeted chemopreventive agents. The company's lead program involves the use of high-dose, locally delivered anti-inflammatory agents designed to reduce the recurrence of adenomatous polyps in high-risk patients. By utilizing proprietary delivery mechanisms, CologRx aims to maximize therapeutic efficacy in the colon while minimizing systemic side effects typically associated with long-term NSAID use. The company's approach targets the cyclooxygenase-2 (COX-2) pathway, which is a well-validated driver of colorectal oncogenesis.